A Hospital-based Approach to Achieving Better Health Outcomes in Heart Failure

Release Date :
July 31, 2018
Expiration Date :
July 31, 2019
FACULTY

Lee Goldberg, MD, MPH
Medical Director
Heart Failure and Cardiac Transplant Program
Associate Professor of Medicine
Cardiovascular Medicine Division
University of Pennsylvania
Philadelphia, Pennsylvania

PROGRAM OVERVIEW

Heart failure (HF) is a condition for which the rates of hospitalization, morbidity, and mortality remain high despite recently updated management guidelines. There is a range of therapeutic options for HF that includes two new medications (sacubitril/valsartan and ivabradine) with the potential to improve outcomes over what has historically been achievable with standard therapies. Although the reasons underlying persistent gaps in the care of patients with HF are not completely clear, evidence indicates that adherence to guideline-directed management and therapy is often suboptimal. Moreover, there appears to be a positive correlation between guideline adherence and the outcomes of hospitalized patients with HF. In light of these observations, it is especially important that healthcare professionals involved in the care of patients with HF maintain current and comprehensive knowledge of the disease and its management. Toward that end, the present program has been developed to aid hospital-based healthcare providers, who are often charged with the care of patients with HF and are well situated to positively influence later outcomes, in navigating new and ongoing developments in the field.

TARGET AUDIENCE

This educational initiative has been designed for hospital-based healthcare providers, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists involved in the management of patients with HF.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Utilize an evidence-based approach to the diagnosis and evaluation of patients with HF that is consistent with current guideline recommendations
  • Summarize current clinical evidence regarding the efficacy and safety of new pharmacologic therapies for the treatment of HF with reduced ejection fraction
  • Implement guideline-directed medical therapy for patients with HF
  • Identify transitional care strategies to prevent disease progression and future hospitalizations among patients with HF
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2018, through July 31, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integrity Continuing Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for a total of 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number – JA4008162-9999-18-320-H01-P)
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.
For information about ACPE or ANCC accreditation of this activity, please contact Postgraduate Institute for Medicine at (303) 799-1930 or inquires@pimed.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education and Postgraduate Institute for Medicine require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Postgraduate Institute for Medicine are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lee Goldberg, MD, MPH
Consultant: Respircardia

The following planner and manager, Patima Tanapat, PhD, hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The PIM planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine and Integrity Continuing Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.

This CEU/CNE activity is co-provided by Postgraduate Institute for Medicine and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGMENT

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Continue to Pretest